Verantos announces breakthrough in non-alcoholic steatohepatitis real-world evidence

• In an observational analysis, traditional approaches resulted in data accuracy of 54.1%; using advanced approaches, however, including unstructured data, natural language processing, and artificial intelligence-based inference, Verantos, Amgen, and Virginia Commonwealth University researchers achieved 78% improved data accuracy
• According to the American Liver Foundation, 25% of Americans have non-alcoholic fatty liver disease (NAFLD) or NASH, and the prevalence is increasing simultaneously with obesity, high cholesterol, and type 2 diabetes
• Natural language processing, a common technique used to mine electronic health record data, resulted in 63.3% and 68.8% accuracy for the key concepts of “alcohol use” and “liver fibrosis”
• “This opens the door to robust research that can benefit patients,”

Dr. Dan Riskin

Founder and CEO

Verantos

Click here to learn more.

About SVMPharma

SVMPharma is an innovative strategic consultancy and CRO, with a focus in Real World Evidence (RWE) for pharmaceutical and biotechnology companies. SVMPharma delivers clinical trials within UK and Europe.

About DISTILL

DISTILL is a new EDC launched by SVMPharma. As a CRO discover the benefits of DISTILL as part of your service offering and take back control of your clinical trials. DISTILL allows you to develop and manage every aspect of your trials from start to finish. Move away from the restrictions and costs associated with legacy systems.

For more information, please visit www.svmpharma.com and contact us at enquiry@svmpharma.com

Ref:RWEAPR2022HBA